

1 October 2021

SourceBio International plc
("SourceBio", the "Company" or "the Group")

Grant of share options

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products, announces that it has granted 4,750,000 share options to Executive Directors and other employees under the Company's new Executive Share Option Plan ("ESOP"), which the Company's Board approved to establish following the passing of a resolution at the Company's AGM in June.

The share options granted were proposed by the Remuneration Committee and approved by the Board. In proposing these option grants the Remuneration Committee was conscious that no options have been granted in the past, in particular since Admission to AIM in October 2020.

The number of shares under the options that have been granted are as follows:

Jay LeCoque, Executive Chairman and Director	2,000,000
Tony Ratcliffe, Chief Financial Officer and Director	1,350,000
Other employees	1,400,000

The options will vest over three years in three equal annual tranches subject to the Rules of the ESOP. For all share options to become exercisable, the performance vesting condition requires a share price of 200 pence or greater, representing a premium of 43% to the closing mid-market price on 29 September 2021 of 140 pence.

For Jay LeCoque the share options have an exercise price of 162 pence per share, being the share price on Admission. This represents a premium of 16% to the closing price of 140 pence on 29 September 2021. All other share options have an exercise price of 140 pence per share, being the closing price on 29 September 2021.

All the share options have a 10-year term from the date of grant (subject to their earlier exercise or lapse in accordance with the rules of the ESOP).

Following the grant of the share options outlined above, the total share options outstanding will be 4,750,000 representing approximately 6.4% of the 74,183,038 ordinary shares in issue.

Contacts:

SourceBio International plc

Jay LeCoque, Executive Chairman
Tony Ratcliffe, Chief Financial Officer

www.sourcebiointernational.com

Via Walbrook PR

Liberum (Nominated Adviser and Broker)

Bidhi Bhoma / Richard Lindley / Euan Brown

Tel: 020 3100 2000

Walbrook PR Limited

Paul McManus / Sam Allen

Tel: 020 7933 8780 or sourcebio@walbrookpr.com

Mob: 07980 541 893 / 07502 558 258

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:

- **Infectious Disease Testing** - a range of COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and the DHSC. Utilising multiple technologies, SourceBio offers screening, gold standard RT-PCR and whole genome sequencing COVID-19 testing solutions and operates under ISO 15189 accreditation required by the DHSC. SourceBio also provides employee testing solutions to industry, and direct to consumer home test kits (including "Fit to Fly", "Test to Release" and "Day 2 & Day 8 International Travel" approved tests).
- **Healthcare Diagnostics** - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
- **Genomics** - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
- **Stability Storage** - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.

More details on Group operations can be found here: www.sourcebioscience.com.

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

**DEALING NOTIFICATION FORM
FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED
PERSONS**

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Jay LeCoque
2.	Reason for the notification
a)	Position/status: Executive Chairman and Director
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name: SourceBio International plc
b)	LEI: 213800KY4C9WU7WBW518
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary shares of £0.0015 each Identification code: GB00BKSB1674

b)	Nature of the transaction: Grant of options				
c)	Price(s) and volume(s): <table border="1" data-bbox="247 315 826 443"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>162p</td> <td>2,000,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	162p	2,000,000
Price(s)	Volume(s)				
162p	2,000,000				
d)	Aggregated information: N/A - Single transaction				
e)	Date of the transaction: 30 September 2021				
f)	Place of the transaction: Outside trading venue				

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Tony Ratcliffe
2.	Reason for the notification
a)	Position/status: Chief Financial Officer and Director
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name: SourceBio International plc
b)	LEI: 213800KY4C9WU7WBW518
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary shares of £0.0015 each Identification code: GB00BKS1674
b)	Nature of the transaction: Grant of options

c)	Price(s) and volume(s): <table border="1" data-bbox="247 190 826 315"> <thead> <tr> <th data-bbox="247 190 534 241">Price(s)</th> <th data-bbox="534 190 826 241">Volume(s)</th> </tr> </thead> <tbody> <tr> <td data-bbox="247 241 534 315">140p</td> <td data-bbox="534 241 826 315">1,350,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	140p	1,350,000
Price(s)	Volume(s)				
140p	1,350,000				
d)	Aggregated information: N/A - Single transaction				
e)	Date of the transaction: 30 September 2021				
f)	Place of the transaction: Outside trading venue				